Last $36.01 USD
Change Today -0.71 / -1.93%
Volume 96.4K
MYGN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 11:18 AM 07/31/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

320 Wakara Way

Salt Lake City, UT 84108

United States

Phone: 801-584-3600

Fax: 801-584-3640

ss of function is associated with more aggressive disease progression and poorer survival. The PTEN gene plays a role in the disease progression of all four of the major cancers—breast, prostate, colon, and lung cancer. The PTEN gene also plays a critical role in cell signaling pathways that are the target cancer drugs, such as EGFR, mTOR and PIK3CA inhibitors. Analysis of PTEN function may help oncologists in identifying patients who may not respond to these classes of cancer drugs. The company owns or has exclusive patent rights to six U.S. patents covering PREZEON testing. Prolaris: A prognostic medicine test for prostate cancer. The company’s Prolaris test is a 46-gene molecular diagnostic assay that assesses whether a patient is likely to have a slow growing, indolent form of prostate cancer that can be safely monitored through active surveillance, or a more aggressive form of the disease that would warrant aggressive intervention such as a radical prostatectomy or radiation therapy. The company owns or has exclusive patent rights to four U.S. patent applications covering Prolaris testing. TheraGuide 5-FU: A personalized medicine test for drug toxicity. The company’s TheraGuide 5-FU test analyzes mutations in the DPYD gene and variations in the TYMS gene to assess patient risk of toxicity to 5-FU (fluorouracil) anti-cancer drug therapy. 5-FU is widely prescribed for the treatment of colorectal cancer, metastatic breast cancer, skin cancer, and head and neck cancers. The company owns or has exclusive rights to two U.S. patent applications covering TheraGuide 5-FU testing. Companion Diagnostic Services As of June 30, 2013, Rules-Based Medicine, Inc. of Austin, Texas, operated as a wholly-owned subsidiary of the company under the name of Myriad RBM, Inc. (Myriad RBM). The acquisition expanded its test pipeline into new disease states, including neuroscience disorders, infectious diseases and inflammatory diseases. The company has strategic collaborations with approximately 20 major pharmaceutical and biotechnology companies. Through Myriad RBM, the company provides biomarker discovery and companion diagnostic services to the pharmaceutical, biotechnology, and medical research industries utilizing its multiplexed immunoassay technology. The company’s companion diagnostic services consist of the following: Multi-Analyte Profile (MAP): The company has compiled a library of approximately 550 individual human and rodent immunoassays for use in its multi-analyte profile (MAP) testing services and the company is continuously adding new assays to this library. The company also has developed RodentMAP, a proprietary panel for use in pre-clinical animal studies and OncologyMAP, which measures cancer-related proteins to assist researchers accelerate the pace of discovery, validation and translation of cancer biomarkers for early detection, patient stratification and therapeutic monitoring. The company has licensed rights to the Luminex platform used in its MAP testing services. Multiplexed Immunoassay Kits: Customers in all segments of the life sciences market often require both outsourced and in-house testing. Many of its pharmaceutical and biotechnology customers need bioassay kits for complimentary in-house testing. The company has licensed rights to the Luminex platform used in its multiplexed immunoassay kits. TruCulture: TruCulture is a simple, self-contained whole blood culture that can be deployed to clinical sites worldwide for acquiring cell culture data without specialized facilities or training. The company has exclusive patent rights to one U.S. patent covering its TruCulture and other co-culture services. Patents and Proprietary Rights The company owns or has license rights to 234 issued patents, as well as various patent applications in the United States and foreign countries. These patents and patent applications cover various subject matter, including diagnostic biomarkers, genes, proteins, gene expression signatures, antibodies, primers, probes, assays, disease-associated genetic mutations and single-nucleotide polymorphisms, methods for determining genetic predisposition, methods for d

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MYGN:US $36.01 USD -0.71

MYGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advanced Drainage Systems Inc $15.80 USD -0.125
Bio-Reference Laboratories Inc $31.33 USD -0.60
Foundation Medicine Inc $22.50 USD -0.84
Genomic Health Inc $25.79 USD -0.56
Imperial Innovations Group PLC 445.00 GBp -5.00
View Industry Companies
 

Industry Analysis

MYGN

Industry Average

Valuation MYGN Industry Range
Price/Earnings 15.6x
Price/Sales 3.6x
Price/Book 3.8x
Price/Cash Flow 14.7x
TEV/Sales 3.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MYRIAD GENETICS INC, please visit www.myriad.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.